{"filing":{"accession_number":"0001477932-26-005251","cik":"0000093314","ticker":"VNRX","company_name":"VOLITIONRX LTD","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-19","primary_document":"vnrx_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226005251/vnrx_8k.htm"},"events":[{"id":29236,"run_id":26750,"accession_number":"0001477932-26-005251","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The Company issued 773,361 shares of common stock (220,264 + 553,097) to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes totaling $9.9 million in principal. The disclosure explicitly states reliance on Section 3(a)(9), Section 4(a)(2), and Rule 506 of Regulation D—all exemptions from registration under the Securities Act—and notes the issuance was to an existing securityholder without general solicitation. This is a classic dilutive equity issuance by a small-cap biotech company to a financial investor, material to shareholders' ownership and voting interests.","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31437,"accession_number":"0001477932-26-005251","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Company issued 773,361 shares of common stock (220,264 + 553,097) to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes totaling $9.9 million in principal. The disclosure explicitly states reliance on Section 3(a)(9), Section 4(a)(2), and Rule 506 of Regulation D—all exemptions from registration under the Securities Act—and notes the issuance was to an existing securityholder without general solicitation. This is a classic dilutive equity issuance by a small-cap biotech company to a financial investor, material to shareholders' ownership and voting interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T21:02:51.709442+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31437,"accession_number":"0001477932-26-005251","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Company issued 773,361 shares of common stock (220,264 + 553,097) to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes totaling $9.9 million in principal. The disclosure explicitly states reliance on Section 3(a)(9), Section 4(a)(2), and Rule 506 of Regulation D—all exemptions from registration under the Securities Act—and notes the issuance was to an existing securityholder without general solicitation. This is a classic dilutive equity issuance by a small-cap biotech company to a financial investor, material to shareholders' ownership and voting interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T21:02:51.709442+00:00","company_name":"VOLITIONRX LTD","ticker":"VNRX","filing_date":"2026-08-24"}]}